Skip to main content

Table 1 The role of surgery in small cell lung cancer

From: Current role of surgery in small cell lung carcinoma

Study

Protocol-Patients

Local relapse

Survival

Fujimori

1997 (22)

P.E based CT × 2–4 → S

5%

Overall MD: 61.9 months (21 pts)

 

Patients: 22

 

3 year: 66.7%

 

Resected pts: 21/22

 

Stage

   

   I-II: 3 year → 73.3%

   

   IIIA: 3 year → 42.9%

   

   p = 0.018

Eberhardt

2003 (13)

Stage IB-IIA: P.E × 4 → S (8 pts)

0%

Overall survival (46 pts)

 

Stage IIB-IIIA: P.E × 3 → concurrent CTRx (Hf-RTx) → S (38)

 

   5 year: 39%

   

   10 year: 35%

 

Resected pts: 30/46 (stage IB-IIA:8/IIB-IIIA:22)

 

Stage IIB-IIIA (22 pts)

   

   5 year: 44%

   

   10 year: 41%

Rostad

2004 (15)

CT or concurrent CTRx: 2404 pts

 

Stage I – 5 year survival

 

Surgery: 38 pts

 

   11.3% (CT or CTRx)

 

   Surgery + additional treatment (CT, RTx, CTRx): 25/38 pts

 

   44.9% (surgery ± additional treatment)

Brock

2005 (19)

S ± adjuvant or induction CT

 

Stage I

   

   5 year: 58%

 

82 pts

  
   

Stages II, III and IV

   

   5 year: 18%, 23%, 0%

   

p < 0.001

Tsuchiya

2005 (20)

S → P.E × 4 (62 pts)

10%

Pathological Stage (5 year survival):

 

Resected pts: 61/62

 

   I: 73%

   

   II: 38%

   

   IIIA: 39%

Granetzny

2006 (14)

S → CTRx (64 pts) – stage I, II

 

MD

   

   Primary S: 31,3 months

 

CT → S → CT + RTx (thoracic, cranial) (31 pts) – stage IIIA, IIIB

 

   S after CT: 31,7 months (N2-), 12.4 months (N2+)

Bischof

2007 (21)

S → CT ± RTx ± PCI

 

MD: 47 months

 

39 pts: CT 35 pts, RTx 16 pts, PCI 21 pts

 

1,3, 5 year survival: 97%, 58%, 49%

Lim

2008 (20)

59 pts: 43 pure SCLC, 16 pts:mixed histology

 

5 year survival: 52%

 

Adjuvant therapy: 16/59

 

T, N, UICC stage not statistically significant

  1. Recent trials supporting the role of surgery in small cell lung cancer (SCLC).
  2. P.E: platinum-etoposside, S: surgery, CTRx: chemoradiotherapy, Hf-RTx: hyperfractionated radiotherapy, CT: chemotherapy, RTx: radiotherapy, MD: median survival.